A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants

作者：Xiaomin Duan, Rui Shi, Pulan Liu, Qingrui Huang, Fengze Wang, Xinyu Chen, Hui Feng, Weijin Huang, Junyu Xiao, Jinghua Yan · 发表于：Signal Transduction and Targeted Therapy · 年份：2022 · DOI：10.1038/s41392-022-00879-2 · 被引用次数：17 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Influenza Virus Research Studies

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. Omicron (B.1.1.529), the fifth novel SARS-CoV-2 variant of concern (VOC), harbors 15 mutations in the receptor-binding domain (RBD) of the spike (S) protein. 1 These mutations include almost all the sites of existing VOCs (Alpha/B.1.1.7, Beta/B.1.351, Gamma/P.1, and Delta/B.1.617.2). 2 , 3 , 4 Importantly, the key mutations directly interact with the ACE2 receptor and constitute the main target of neutralizing antibodies (NAbs), which is believed to alter the sensitivity to a large number of NAbs.